Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In Japan, sales of closed systems for drug preparation and administration and surgical gloves increased, while overseas sales of AVF needles remained firm and sales of blood bags and dialysis chairs for Europe declined. Savings in manufacturing expenses and other costs had a positive effect, but lower sales of major overseas products and increases in personnel expenses and research and development expenses affected profit.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥15,128 million (YoY -2.7%) |
| Operating profit | ¥-121 million |
| Ordinary income | ¥-114 million |
| Profit attributable to owners of the parent | ¥-379 million |
| Net income per share | ¥(15.48) |
| Equity ratio | End of the current fiscal period 50.3 / End of previous period 50.2 |
| Total assets | ¥82,817 million |
| Net assets | ¥41,716 million |
| Full-year earnings forecast | Net Sales ¥66,000 million (YoY +0.2%) / Operating profit ¥1,000 million (YoY +162.1%) / Ordinary income ¥900 million (YoY +152.4%) / Net income ¥600 million |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥17 → ¥17（0.0%） |
| Segment revenue | Japan ¥10,574 million (YoY +0.3%), Singapore ¥5,191 million (YoY -7.9%), China ¥1,181 million (YoY +28.0%), Philippines ¥901 million (YoY +7.4%), Germany ¥956 million (YoY -11.5%), Other ¥1,121 million (YoY -24.4%) |
| Segment profit | Japan ¥145 million (YoY +19.9%), Singapore ¥-124 million, China ¥111 million, Philippines ¥-160 million, Germany ¥104 million (YoY -19.1%), Other ¥-54 million |
| Depreciation and amortization | ¥981 million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥3 million / Extraordinary loss Loss on sale of fixed assets ¥2 million, Loss on disposal of fixed assets ¥3 million |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 24,733,466 Shares |
| Treasury Shares at Period-End | 202,973 Shares |
| Factors Behind Changes in Business Performance | In Japan, sales of closed systems for drug preparation and administration and surgical gloves increased, while overseas sales of AVF needles remained firm and sales of blood bags and dialysis chairs for Europe declined. Savings in manufacturing expenses and other costs had a positive effect, but lower sales of major overseas products and increases in personnel expenses and research and development expenses affected profit. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, sales of closed systems for drug preparation and administration and surgical gloves increased. Overseas, sales of AVF needles remained firm, while sales of blood bags and dialysis chairs for Europe declined. In terms of profit, savings in manufacturing expenses and other costs had a positive effect, but lower sales of major overseas products, including blood bags, and increases in personnel expenses and research and development expenses had an impact.